Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 18/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | ABL2 | P42684 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.33 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201023 | 0.90 | RIPK1 (0.49) | ABL1RIPK1RIPK2RIPK3ABL2 | |
| SCHEMBL16084979 | 0.81 | RIPK1 (0.46) | ABL1RIPK1RIPK2RIPK3ABL2 | |
| SCHEMBL16084982 | 0.76 | RIPK1 (0.55) | ABL1RIPK1RIPK2RIPK3 | |
| SCHEMBL16084945 | 0.71 | RIPK1 (0.59) | ABL1RIPK1RIPK2RIPK3LCK | |
| SCHEMBL16084986 | 0.70 | RIPK1 (0.60) | ABL1RIPK1RIPK2RIPK3 | |
| SCHEMBL16084981 | 0.69 | RIPK1 (0.62) | ABL1RIPK1RIPK2RIPK3 | |
| SCHEMBL16084950 | 0.68 | RIPK1 (0.78) | ABL1RIPK1RIPK2RIPK3LCK | |
| SCHEMBL16084947 | 0.67 | RIPK1 (0.68) | ABL1RIPK1RIPK2RIPK3ABL2 | |
| SCHEMBL11327211 | 0.65 | ABL1 (0.63) | ABL1ABL2 | |
| SCHEMBL588526 | 0.64 | ABL1 (0.54) | ABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323489-A1 | HYBRID NECROPTOSIS INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323489-A1 | HYBRID NECROPTOSIS INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323489-A1 | HYBRID NECROPTOSIS INHIBITORS | RIPK3, RIPK1, RIPK4 | ABL1 1547/4885RIPK1 2/4885RIPK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.